Abstract
AKI, a serious, common and occasionally under-recognized condition, which is a significant contributor to the growing incidence of CKD and end-stage renal disease (ESRD). To date, the diagnosis of AKI is made by serial measurement of Cr and BUN which are late and imprecise markers of kidney injury. “Calprotectin” and “endocan” are two biomarkers that could reflect renal tubular injury and glomerular/endothelial-vascular damage, respectively. Measurement of urinary calprotectin could help the physicians to diagnose tubular degradation and differentiate prerenal AKI from intrinsic AKI. Serum level of endocan could signify endothelial damage. Herein it is hypothesized that calprotectin and endocan may help the clinicians to diagnose intrinsic AKI, earlier than rise of serum creatinine, differentiate AKI from acute presentation of CKD and also discriminate tubular injury from glomerular/vascular-endothelial injury, assess the prognosis and extent of renal damage and plan for appropriate therapy which may render these biomarkers as potentially applicable equivalents of Troponin in the field of nephrology.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
